Elicera Therapeutics’ warrants (TO1) are listed on First North Growth Market

The first trading day for the ELIC TO1 warrants will be Wednesday 7 July 2021.

The warrants ELIC TO1, which were received free of charge by subscribers of Units in connection with the listing are under distribution., The warrants have will be traded with the first trading day on the Nasdaq First North Growth Market with first day 7 July 2021.

The warrant (TO1) gives for each two (2) warrants the right to subscribe for one (1) new share at a price of SEK 11.60 during the period 1 November-30 November 2022. Full terms and conditions are available on the Company's website, www.elicera.com.

The number ELIC TO1 is 7,500,000 pieces and the ISIN code is SE0015988233.

For further information please contact:

Jamal El-Mosleh, CEO, Elicera Therapeutics AB

Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com

About Elicera Therapeutics AB

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer. The Company’s share (ELIC) is traded on Nasdaq First North Growth Market. G&W Fondkommission has been appointed the Company's Certified Adviser. E-mail: ca@gwkapital.se, tel: +468-503 000 50.

For more information, please visit www.elicera.com